PDS BIOTECH ANNOUNCES PUBLICATION OF VERSATILE-002 PHASE 2 CLINICAL TRIAL RESULTS OF PDS0101 WITH PEMBROLIZUMAB IN HPV16-POSITIVE RECURRENT AND/OR METASTATIC (R/M) HEAD AND NECK CANCER IN JAMA ONCOLOGY

Reuters · 1d ago

Please log in to view news